IL37 and systemic lupus erythematosus: In a phase two trial of 102 adult patients with active SLE, the addition to standard-of-care treatment of Ustekinumab, a human IgG1k monoclonal antibody targeting both the IL-12 and IL-23 cytokines, resulted in better efficacy in clinical and laboratory parameters than placebo.